News: Xenon unable to Pass 2b Trials $XENE
Teva Pharmaceutical Industries Ltd. and Xenon Pharmaceuticals Inc., has jointly conducted the placebo-controlled Phase 2b study designed to evaluate the safety and efficacy of topically applied TV-45070 (4% and 8% w/w ointment) in patients with chronic pain due to osteoarthritis (OA) of the knee. The results were not sufficient to make any difference from placebo in […]
News: Xenon unable to Pass 2b Trials $XENE Read More »
